No abstract available.
Carboplatin* ; Cytarabine* ; Cytosine* ; Etoposide*

No abstract available.
Child* ; Cytarabine* ; Cytosine* ; Humans ; Leukemia*

Myelodysplasia syndrome is a diseases group of which quite difficult cure and prediction. There are many treatment methods however it depends on patient’s age, level of diease, rate of blast in bone marrow. The treatment includes: chemical treatment, trasplant originative cell, support treatment. Other method is combination of various treatment methods: Use Ara-C combine with depersolon, chemical treatment combine with stimulative agent of blood and trasplant originative cell
Neural Tube Defects ; Bone Marrow ; Cytarabine ; Therapeutics

No abstract available.
Bendamustine Hydrochloride* ; Cytarabine* ; Drug Therapy* ; Lymphoma*

To know the effect of subconjunctival injection of liposome encapsulated cytarabine on proliferation of conjunctival fibroblasts, the conjunctiva was isolated at 180 degrees from the injection site 3 days after subconjunctival injection of the normal saline (control), cytarabine, liposome encapsulated cytarabine, and 1 day after injection of cytarabine, and then those were inoculated in the culture media of fibroblasts. In the case of 3 days after injection of cytarabine, there was 49% and 42% inhibition of proliferation of conjunctival fibroblasts compared with the control respectively. Therefore, the authors concluded that the liposome encapsulated cytarabine is effective on inhibition of proliferation of conjunctival fibroblasts and reduces the frequencies of subconjunctival injection compared with the cytarabine itself.
Conjunctiva ; Culture Media ; Cytarabine* ; Fibroblasts* ; Liposomes*

No abstract available.
Cisplatin* ; Cytarabine* ; Drug Therapy* ; Pleural Effusion, Malignant*

No abstract available.
Adult* ; Cytarabine* ; Cytosine* ; Humans ; Leukemia* ; Mitoxantrone*

No abstract available.
Cytarabine* ; Drug Therapy, Combination* ; Leukemia, Myeloid, Acute*

OBJECTIVETo investigate the role of Ara-C in regulating anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.

METHODSThe diabody of anti-CD3/anti-Pgp was purified by E-tag affinity chromatography. K562 and K562/A02 cells were treated with Ara-C. The expressions of B7-1 and B7-2 on K562 and K562/AO2 cells were detected by FACS. The cytotoxicity of T-lymphocytes combined with anti-CD3/anU-Pgp plus Ara-C was analyzed by CytoTox 96 nonradioactive method.

RESULTSThe expressions of B7-1 and B7-2 on K562 and K562/A02 cells treated by Ara-C was significantly higher than those untreated. The effect/target ratio was from 0.39:1 to 25:1, and the killing rate of activated T cells to anti-drug-resistant leukemia cells was from (16.44 +/- 1.20)% to (60.49 +/- 2.90)%. The killing rates were increased gradually, with both the effect/target ratio and the antibody concentration increasing (P < 0.05).

CONCLUSIONAra-C may be an important adjuvant for improving anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.

No abstract available.
Cytarabine* ; Cytosine* ; Drug Therapy, Combination* ; Idarubicin* ; Leukemia, Myeloid, Acute*